"Plasma Protein and Red Blood Cell Binding of WR238605, A Candidate Antimalarial Drug."

According to an abstract submitted by the authors to the 97th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, held March 20-22, 1996, in Lake Buena Vista, Florida, "The plasma protein and red blood cell (rbc) binding characteristics of ¹⁴C-WR238605, a candidate antimalarial drug, were investigated in vitro using samples from six human donors and six beagle dogs. Using equilibrium dialysis and dextran-coated charcoal (DCC) methods, the binding capacity and affinity were studied. WR238605 was 91-99% protein bound in undiluted human and canine plasma. There appeared to be a trend towards lower binding at lower drug concentrations, with 91.4...

Want to see the full article?

• Purchase this article for only $3.00